A single dose of pegylated IFN-lambda (IFN-L) showed similar efficacy to nirmatrelvir (Paxlovid) when studied in comparable patient populations (vaccinated, high risk) in placebo controlled studies.  

IFN-L data:

https://dcricollab.dcri.duke.edu/sites/NIHKR/KR/GR-Slides-07-29-22.pdf

IFN-L is a long-acting version of a natural human protein.  It stimulates the host immune system instead of inhibiting the virus.  It's a more sustainable therapy that is less likely to result in the creation of drug-resistant viral variants.  IFN-L does not have all the drug-drug interaction issues created by ritonavir.  It has a long-established safety profile based on a decade of work evaluating IFN-L in other diseases.  

People at high risk for hospitalization or death from covid19 should have access to IFN-L.  At a minimum, Eiger Biopharmaceuticals should be enabled and encouraged to apply for emergency use authorization, and an advisory committee meeting should be held.